It may not seem like Sarepta Therapeutics, Inc. is taking a big risk by pursuing accelerated approval of Duchenne muscular dystrophy (DMD) treatment SRP-9001 (delandistrogene moxeparvovec) after already winning US Food and Drug Administration accelerated approvals for three exon-skipping DMD drugs. However, as a one-time gene therapy with a potentially high upfront cost, SRP-9001 may face a different type of scrutiny once it hits the market – though that will likely be several months before its closest competitor.
Given that Sarepta investors have mostly focused this year on whether or not the biotech would try to beat








